Creo Medical Group PLC (LON:CREO – Get Free Report) insider Richard John Rees acquired 6,250 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were acquired at an average cost of GBX 14 per share, with a total value of £875.
Creo Medical Group Price Performance
CREO stock traded up GBX 0.01 on Monday, reaching GBX 14.57. The company had a trading volume of 1,405,552 shares, compared to its average volume of 871,779. The company’s fifty day moving average is GBX 13.18 and its 200 day moving average is GBX 12.90. The company has a market cap of £70.81 million, a P/E ratio of 14.57 and a beta of 1.62. The company has a debt-to-equity ratio of 8.20, a quick ratio of 2.19 and a current ratio of 3.22. Creo Medical Group PLC has a 1 year low of GBX 9.52 and a 1 year high of GBX 18.50.
Creo Medical Group (LON:CREO – Get Free Report) last released its quarterly earnings results on Friday, May 22nd. The company reported GBX (0.04) earnings per share for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%.The company had revenue of GBX 600 million for the quarter. On average, research analysts forecast that Creo Medical Group PLC will post -10.0800005 earnings per share for the current year.
Analyst Upgrades and Downgrades
Creo Medical Group Company Profile
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.
Featured Stories
- Five stocks we like better than Creo Medical Group
- This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
- These 3 Stocks Offer Investors Exposure to the Functional Beverage Boom
- Alcoa’s $4.1 Billion South32 Deal: Opportunity Behind the 9% Drop
Receive News & Ratings for Creo Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creo Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
